Rewrite the Message
Deliver the Hope
Jorna Therapeutics is developing novel RNA editors using cutting-edge AI models,
so that we can rewrite critical life messages not just in letters,
but in meaningful paragraphs
Change the message,
Without having to risk tampering with the genome
1
Target the transcripts, not genomes
By only targeting the mRNA, not the genomic DNA, we do not risk genomic off-target editing, which is usually irreversible and can have profound toxicity.
2
High Editing Efficiency
Unlike genome editing, whose edit efficacy is subject to various factors such as cell type/state, chromosome structure, etc, our technology can achieve high editing efficiency consistently across many conditions.
3
Multiple modes of action
Compared with gene replacement therapies, our technology produces desired products at native expression levels, due to the fact that the endogenous regulatory circuitry and modifications are kept intact.
4
Paragraphs instead of just letters
Our technology enables large fragment editing on the target mRNA, so that patients with various mutations of the same gene could be treated with one unified therapy.
5
Editors, Generated by AI
Our RNA editors are designed and optimized using proprietary LLMs and high-throughput screening approaches. This solution is only made possible with the merge of these two platforms.
Built by AI and Gene Therapy Experts
Jorna Therapeutics is a vibrant startup founded by scientists from the Broad Institute and Harvard working on AI-guided editor design and associated therapeutics. In the past, our work has helped our clients such as Sherlock Biosciences and the Gates Foundation tackle some unique challenges that they faced, which in turn formed the basis of our cutting-edge platform. Now we are taking on some of the most challenging problems in this field that could have a profound impact in how we treat genetic and degenerative diseases. We are inviting the most brilliant minds to join us on this exciting journey.
Jorna Therapeutics is a spin-off from Quantum Sky, a proud resident of LabCentral and the recipient of the Diamond Ticket by Astellas in 2024. We are currently located at 238 Main St, Cambridge, MA 0214.
